Sun, 29 Jan 2023

NEW YORK, NY / ACCESSWIRE / November 25, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CNTA Shareholders Click Here: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=34036&wire=1
SQ Shareholders Click Here: https://www.zlk.com/pslra-1/block-inc-lawsuit-submission-form?prid=34036&wire=1
TSP Shareholders Click Here: https://www.zlk.com/pslra-1/tusimple-class-action-loss-submission-form?prid=34036&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Friday, November 25, 2022, Press release picture

Centessa Pharmaceuticals plc (NASDAQ:CNTA)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.
Lead Plaintiff Deadline : November 28, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=34036&wire=1

According to the filed complaint, (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Block, Inc. (NYSE:SQ)

SQ Lawsuit on behalf of: investors who purchased November 4, 2021 - April 4, 2022
Lead Plaintiff Deadline : December 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/block-inc-lawsuit-submission-form?prid=34036&wire=1

According to the filed complaint, during the class period, Block, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate protocols restricting access to customer sensitive information; (2) as a result, a former employee was able to download certain reports of the Company's subsidiary, Cash App Investing, containing full customer names and brokerage account numbers, as well as brokerage portfolio value, brokerage portfolio holdings and/or stock trading activity; (3) as a result, the Company was reasonably likely to suffer significant damage, including reputational harm; (4) and as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

TuSimple Holdings Inc. (NASDAQ:TSP)

This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple securities pursuant and/or traceable to documents issued in connection with TuSimple's April 15, 2021 initial public offering ; and/or (b) purchased or otherwise acquired TuSimple securities between April 15, 2021 and October 31, 2022, both dates inclusive.
Lead Plaintiff Deadline : January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tusimple-class-action-loss-submission-form?prid=34036&wire=1

According to the filed complaint, (1) TuSimple was engaged in undisclosed related party transactions with Hydron, a company founded by TuSimple's co-founder, Mo Chen; (2) TuSimple shared confidential information and/or proprietary technology with Hydron without the approval of TuSimple's board of directors or informing regulators or TuSimple shareholders; (3) TuSimple failed to disclose the internal investigation by its board of directors into the Company's ties to Hydron, which commenced in July 2022; (4) the aforementioned conduct enhanced the likelihood of regulatory scrutiny and investigatory action toward the Company; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/728480/CLASS-ACTION-UPDATE-for-CNTA-SQ-and-TSP-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

More San Diego News

Access More

Sign up for San Diego News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!